Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have hearing loss in both ears caused by a problem with how the inner ear or hearing nerve sends signals to the brain (including a specific type called auditory neuropathy)
- People who have a change (mutation) in the otoferlin gene, which is linked to this type of hearing loss
- People who are willing and able to follow all study requirements and have completed the consent process
For the active monitoring part of the study, there is one extra requirement:
- People who have specific hearing test results — one type of test showing a response (OAEs or cochlear microphonics) while another type (ABR) shows absent or abnormal results — in at least one ear that does not have a cochlear implant, tested within the past 12 months or at the first study visit
Who may not be able to join:
- People (or their legal representatives) who are unable or unwilling to follow all study requirements
- People who have a problem with the structure or size of the hearing nerve itself (cochlear nerve deficiency or dysplasia)
For the active monitoring part of the study, there are additional reasons a person may not be eligible:
- People who have cochlear implants in both ears, or who are planning to receive them in the next 6 months
- People who have a middle ear implant or a brainstem implant, or who are planning to receive one within the next 6 months
- People who have any condition that the study doctor believes would prevent them from completing all follow-up visits or makes participation unsuitable (confirm with trial site)
Note: Eligibility is not based on sex, gender, race, or ethnicity.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Marks, MD, Eli Lilly and Company
Phone: +1 857 410 1816
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
ABR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.